Member login

Forgot Password?
Return to login
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

British Biosimilars Association (BBA) Stakeholder Forum, Tuesday, November 21. Click on the link below for a programme of events. (PDF download)

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

01.02.2018
RT @medicinesforEU: We live in an era of #biologic medicines. Do you know what that means for you? https://t.co/JEhsytenuI #BiosimilarsGoGlobal #AskaboutBiosimilars #BiologicsForAll
29.12.2017
RT @manchempharma: Life Science Industry Coalition position paper released @ABPI_UK @BIA_UK @Britishgenerics @EFPIA @aesgp @EUCOPE @EuropaBio @medicinesforEU @PAGBselfcare @EBE_EU @BritBiosimilars | https://t.co/8vmtRM0hd8
29.12.2017
RT @OfficialNIHR: Focus on #biosimilars: listen to Paul Schofield of @BritBiosimilars and NAPP Pharmaceuticals on the uptake and access of biosimilar medicines, now and in the future https://t.co/G46uDQTNji
29.12.2017
RT @NIHRCRN: Focus on #biosimilars - new video content available: Paul Schofield, Associate Medical Director of the @BritBiosimilars and Medical Director of NAPP Pharmaceuticals presentation: Uptake and access of biosimilar medicines, now and in the future. https://t.co/wLMHrmUBBO
27.11.2017
RT @NYLCandCLL: Interesting @BritBiosimilars CONF as @NHSEngland @NHSImprovement @NHSCC discuss @infliximab switch lessons applied to @rituximab #education #collaboration sustainable strategies & real world data collection important @LeukaemiaCareUK